Skip to content
China Patent Strategy

Latest Updates on the IP Landscape in China

  • Eagle IP
  • About Our Contributors
  • Eagle IP
  • About Our Contributors
  • China,  China Patent Office,  CNIPA,  Inventions,  Patent Term Extension,  PTE

    A More Detailed Overview of China’s Patent Term Extension (PTE) System

    June 17, 2024

    Although PTE has been in the Chinese Patent Law since the 4th Amendment of the law came into effect June 1, 2021, we didn’t really know the exact details of how it operated until the Implementation Regulations and Examination Guidelines (“Implementation Regulations”) were finally released in December 2023. New Rules 77-84 in the Implementation Regulations discuss patent term compensation due to regulatory delay (“PTE”). In this article, we consolidate our summary about PTE based on these latest updates. Highlights Patent Term Extension (PTE) Article 42.3 of the Patent Law states that “[i]n order to compensate for the time taken for the review and approval process before the marketing of a…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
  • Biotech,  China,  Patent Term Extension,  Pharma,  Proposed Changes,  Updates and Changes

    China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

    October 19, 2021

    The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released Draft Patent Examination Guidelines in conjunction with the new Patent Law. We have provided a summary of the key points at this link, and for the next several posts, we will explore some of those topics in greater detail. “PTA” in the Patent Law Patent term compensation for patent office delay, which we will refer…

    Read More
    eagleip No Comments

    Related Posts

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018

    No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

    November 23, 2018

    Diagnostic Claims in China

    January 9, 2020
  • China,  Patent Linkage,  Patent Term Extension,  Updates and Changes

    CHINA: New Patent Examination Guidelines Now Available for Public Comment

    August 4, 2021

    Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses on the following points: We will study these in detail and will focus more closely on points 1-5 in subsequent articles. Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau. This article is for general informational purposes…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
 Older Posts

Subscribe!

Don't miss a post! Subscribe here to join our mailing list. We will never share your contact information with anyone else.
Loading

Recent Posts

  • Apr 13, 2026 Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents
  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
  • Jan 07, 2026 Thin Disclosure but “Bulletproof” Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data

Categories

Archives

  • April 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • September 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • April 2022
  • February 2022
  • December 2021
  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • June 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018

Popular Posts

  • New Policies to Promote Importation of Innovative Drugs
  • Foreign companies transferring IP out of China: things to know
  • Is it Sufficient to Claim an Antibody only by Describing its Antigen?
  • Can Post Filing Data Overcome Inventive Step in China?
  • No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Recent Posts

  • Apr 13, 2026 Please “Mind the Traps”: Four Common Misconceptions About Hong Kong Patents
  • Feb 27, 2026 A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case
  • Jan 29, 2026 What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents
  • Jan 23, 2026 Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data
  • Jan 07, 2026 Thin Disclosure but “Bulletproof” Protection: How a Salt Form Patent was Upheld in China Despite Minimal Data
  • Nov 13, 2025 The Secret Prior Art Trap: A Case Study on Conflicting Applications in China
  • Oct 21, 2025 From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China
  • Sep 30, 2025 When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents
  • Sep 18, 2025 Obviousness: can features from different categories of products be combined to invalidate a design patent?
  • Sep 04, 2025 NMPA’s Releases Draft Measures for Data Protection (Data Exclusivity)
© 2026 Eagle IP Limited
Savona Theme by Optima Themes